Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3
Primary Industries
- Drugs
- Diagnostic
- cardiac
- Imaging
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 369377
Patents relate to Method For Improving Insulin Sensitivity Using An Adenosine Receptor Antagonist, and, Methods And Compositions For Treating Inflammatory Response.
Stedivaze is a potential best-in-class vasodilator for use in cardiac stress testing. The study will evaluate the safety and efficacy of Stedivaze (apadenoson) for use as a pharmacologic stress agent in myocardial perfusion imaging (MPI), a method for detecting defects in the blood supply to the heart. The Phase III trial will also compare the tolerability of Stedivaze to adenosine, a standard pharmacologic stress agent used in MPI scans.
IPSCIO Record ID: 372567
— Licensor grants an exclusive, except as to Licensor and Licensor Affiliates, license, with the right to sublicense, to use the Collaborative Clinical Data in the Licensor Field and the Licensor Clinical Data in the Development Field outside of the Territory to develop, make, have made, use, market, export and import any pharmaceutical products.
Licensor grants an exclusive, except as to Licensor and Licensor Affiliates, license, with the right to sublicense, to use Licensor Manufacturing Technology and Improvements thereto that are Controlled by Licensor in the Development Field to develop, make, have made, use, market, export and import any pharmaceutical products, including any Licensed Products, outside of the Territory.
In addition, Licensor grants a non-exclusive license to use Licensor Manufacturing Technology and Improvements thereto that are Controlled by Licensor in the Development Field to develop, make, have made, use, other than for marketing or sale, and export any pharmaceutical products, including any Licensed Products, inside the Territory, but only to in connection with and in support of Licensors exclusive license.
Licensor grants to an exclusive, except as to Licensor and Licensor Affiliates, license, with the right to sublicense, to use and practice all other Licensor Development Technology Controlled by Licensor, other than the Collaborative Clinical Data, the Licensor Clinical Data, the Licensor Manufacturing Technology, and Improvements to any of the foregoing, outside of the Territory to develop, make, have made, use, market, sell, export and import any pharmaceutical products, including any Licensed Products.
The patents include
N-Pyrazole A2A Receptor Agonists;
C-Pyrazole A2A Receptor Agonists;
Partial A2A Adenosine Receptor Agonists;
Myocardial Perfusion Imaging Method;
Use of A2A Adenosine Receptor Agonists;
Selective A2A Agonist attenuates coronary vasoconstriction induced by lowering perfusion pressure in mouse isolated hearts; and,
Method of Preventing Reperfusion Injury.
IPSCIO Record ID: 372578
This amendment addresses performing the CHAMPION-PHOENIX Study, and financial considerations.
CHAMPION-PHOENIX Study shall mean a repeat phase III prospective, randomized, double blind, standard clopidogrel care controlled, parallel group, superiority study in which the primary objective is to demonstrate that the efficacy of Cangrelor ( combined with 600mg of clopidogrel) is superior to that of usual care, in patients requiring percutaneous coronary intervention (PCI) as measured by a composite of all cause mortality, myocardial infarction (Ml), IDR and stent thrombosis which will be performed under US IND 56,812.
Ticagrelor Product shall mean Licensor s pharmaceutical product containing the pharmaceutical compound known as ticagrelor, a reversibly binding oral P2Y12 adenosine di phosphate (ADP) receptor antagonist.